Halassy subsequently underwent a year of trastuzumab therapy and remains cancer-free, marking 45 months without recurrence!

Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose ...

Beata Halassy, an expert infectious disease researcher, treated her own stage 3 breast cancer by injecting the tumour with ...

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

What led to the muted performance in the generics business? Generics revenue was Rs 624 crore, a decline of 8% YoY, ...

On the evening of 7 November 2024, The Asset, a renowned Asian financial magazine, held 'The Asset ESG Corporate Awards 2024' awards ceremony at the Four Seasons Hotel Singapore. Fosun International ...

ADCs, including the widely used cancer drug Enhertu (trastuzumab deruxtecan), represent a new wave of targeted therapies.

Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China’s ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Virologist treats breast cancer with oncolytic virotherapy, shrinking the tumor and boosting immune response. An ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...